Edition:
India

Active Biotech AB (ACTI.ST)

ACTI.ST on Stockholm Stock Exchange

2.60SEK
8 Apr 2020
Change (% chg)

-0.20kr (-7.14%)
Prev Close
2.80kr
Open
2.82kr
Day's High
2.84kr
Day's Low
2.60kr
Volume
242,296
Avg. Vol
306,511
52-wk High
4.20kr
52-wk Low
2.00kr

Latest Key Developments (Source: Significant Developments)

Active Biotech Q4 Operating Loss Widens To SEK 11.2 Mln
Thursday, 6 Feb 2020 

Feb 6 (Reuters) - Active Biotech AB ::YEAR-END REPORT JANUARY - DECEMBER 2019.Q4 OPERATING LOSS SEK 11.2 MILLION VERSUS LOSS SEK 7.1 MILLION YEAR AGO.Q4 NET SALES SEK 0.9 MILLION VERSUS SEK 4.8 MILLION YEAR AGO.  Full Article

Active Biotech AB Q3 Operating Loss Widens To SEK 9.3 Mln
Thursday, 14 Nov 2019 

Nov 14 (Reuters) - Active Biotech AB ::REG-ACTIVE BIOTECH INTERIM REPORT JANUARY – SEPTEMBER 2019.Q3 NET SALES SEK 0,9 MILLION VERSUS SEK 4.7 MILLION YEAR AGO.A NEW BUSINESS PLAN FOR LAQUINIMOD AND TASQUINIMOD, BASED ON EXTENSIVE PRECLINICAL AND CLINICAL DATA PREVIOUSLY GENERATED, IS IN PROGRESS.Q3 OPERATING LOSS SEK 9.3 MILLION VERSUS LOSS SEK 6.7 MILLION YEAR AGO.DATA ON LAQUINIMOD FROM PHASE 2 LEGATO-HD STUDY IN HUNTINGTON'S DISEASE WAS PRESENTED AT INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS.  Full Article

Active Biotech: Election Committee Proposes Michael Shalmi As Chairman
Thursday, 2 May 2019 

May 2 (Reuters) - Active Biotech AB ::REG-THE ELECTION COMMITTEE OF ACTIVE BIOTECH AB PROPOSES MICHAEL SHALMI TO BE APPOINTED NEW CHAIRMAN OF THE BOARD AND ULI HACKSELL TO BE APPOINTED NEW MEMBER OF THE BOARD.  Full Article

Active Biotech Partner NeoTX Enters Clinical Collaboration With AstraZeneca
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Active Biotech Ab ::REG-ACTIVE BIOTECH'S PARTNER NEOTX ENTERS CLINICAL COLLABORATION WITH ASTRAZENECA TO EVALUATE ANYARA IN COMBINATION WITH IMFINZI® (DURVALUMAB) IN THE UPCOMING PHASE 1B/2 STUDY.NEOTX WILL SPONSOR STUDY, WHILE ASTRAZENECA WILL SUPPLY DURVALUMAB.UNDER TERMS OF AGREEMENT, NEOTX AND ASTRAZENECA WILL COLLABORATE ON A NON-EXCLUSIVE BASIS TO EVALUATE COMBINATION OF TWO DRUGS IN SOLID TUMORS.NEOTX WILL SPONSOR STUDY, WHILE ASTRAZENECA WILL SUPPLY DURVALUMAB.  Full Article

Active Biotech Updates On Financial Position
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Active Biotech AB ::REG-ACTIVE BIOTECH PROVIDES UPDATED INFORMATION ABOUT THE COMPANY'S FINANCIAL POSITION.HAS AGREED WITH BANK THAT PROCESS OF DIVESTMENT OF PROPERTY WILL CONTINUE EVEN AFTER TURN OF YEAR.AGREED WITH BANK THAT LOAN AGREEMENT WILL CONTINUE ON OTHERWISE UNCHANGED TERMS.  Full Article

Active Biotech Reports Qtrly Net Sales SEK 4.7 Million
Thursday, 15 Nov 2018 

Nov 14 (Reuters) - Active Biotech AB ::QTRLY NET SALES SEK 4.7 MILLION VERSUS SEK 5.1 MILLION.QTRLY LOSS PER SHARE SEK 0.06.  Full Article

Active Biotech says new data from the phase 2 Legato-HD study will be presented at HSG 2018
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Active Biotech AB ::REG-ACTIVE BIOTECH: NEW DATA FROM THE PHASE 2 LEGATO-HD STUDY WILL BE PRESENTED AT HSG 2018.IN ADDITION TO PREVIOUSLY PRESENTED DATA ON PRIMARY AND SECONDARY ENDPOINTS AND SAFETY PROFILE, RESULTS FOR EXPLORATORY ENDPOINTS WILL BE PRESENTED.DATA FOR Q-MOTOR, A SENSITIVE, STANDARDIZED RATE-INDEPENDENT AND UNBIASED MEASURE, REVEALED NOMINAL IMPROVEMENT ON MOTOR COORDINATION IN PATIENTS TREATED WITH LAQUINIMOD.THESE DATA TOGETHER WITH THE STRONG TREATMENT EFFECT ON BRAIN VOLUME LOSS PROPOSE A CENTRAL EFFECT OF LAQUINIMOD IN THE LEGATO-HD STUDY.ADDITIONAL ANALYSIS OF THE STUDY IS ONGOING AND FURTHER RESULTS WILL BE PRESENTED AT UPCOMING SCIENTIFIC MEETINGS.  Full Article